Risk of disease flares after SARS-CoV-2 mRNA vaccination in patients with systemic lupus erythematosus

References

• Conway R, Grimshaw AA, Konig MF, et al. SARS-CoV-2 infection and COVID-19 outcomes in rheumatic diseases: a systematic literature review and meta-analysis. Arthritis Rheumatol. 2022;74(5):766–775. doi: 10.1002/art.42030.
   PubMed Web of Science ®Google Scholar
• Cordtz R, Kristensen S, Dalgaard LPH, et al. Incidence of COVID-19 hospitalisation in patients with systemic lupus erythematosus: a nationwide cohort study from Denmark. J Clin Med. 2021;10(17):3842.
   PubMed Web of Science ®Google Scholar
• Tenforde MW, Patel MM, Gaglani M, et al. Effectiveness of a third dose of Pfizer-BioNTech and moderna vaccines in preventing COVID-19 hospitalization among immunocompetent and immunocompromised adults – United States, August–December 2021. MMWR Morb Mortal Wkly Rep. 2022;71(4):118–124. doi: 10.15585/mmwr.mm7104a2.
   PubMed Web of Science ®Google Scholar
• Putman M, Kennedy K, Sirotich E, et al. COVID-19 vaccine perceptions and uptake: results from the COVID-19 global rheumatology alliance vaccine survey. Lancet Rheumatol. 2022;4(4):e237–e240. doi: 10.1016/S2665-9913(22)00001-7.
   PubMedGoogle Scholar
• Clark LR, Sawkin MT, Melton BL, et al. The COVID-19 vaccine conundrum: an assessment of vaccine hesitancy amongst patients at a federally qualified health center. J Pharm Pract. 2022;36(6):1350–1355.
   PubMed Web of Science ®Google Scholar
• Izmirly PM, Kim MY, Samanovic M, et al. Evaluation of immune response and disease status in systemic lupus erythematosus patients following SARS-CoV-2 vaccination. Arthritis Rheumatol. 2022;74(2):284–294. doi: 10.1002/art.41937.
   PubMed Web of Science ®Google Scholar
• Felten R, Kawka L, Dubois M, et al. Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study. Lancet Rheumatol. 2021;3(9):e613–e615. doi: 10.1016/S2665-9913(21)00221-6.
   PubMedGoogle Scholar
• Fan Y, Geng Y, Wang Y, et al. Safety and disease flare of autoimmune inflammatory rheumatic diseases: a large real-world survey on inactivated COVID-19 vaccines. Ann Rheum Dis. 2022;81(3):443–445. doi: 10.1136/annrheumdis-2021-221736.
   PubMed Web of Science ®Google Scholar
• Mok CC, Chan KL, Tse SM. Hesitancy for SARS-CoV-2 vaccines and post-vaccination flares in patients with systemic lupus erythematosus. Vaccine. 2022;40(41):5959–5964. doi: 10.1016/j.vaccine.2022.08.068.
   PubMed Web of Science ®Google Scholar
• Yoshida T, Tsuji H, Onishi A, et al. Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus. Lupus Sci Med. 2022;9(1):e000727. doi: 10.1136/lupus-2022-000727.
   PubMed Web of Science ®Google Scholar
• Jagtap K, Naveen R, Day J, et al. Flares in autoimmune rheumatic diseases in the post-COVID-19 vaccination period - A cross-sequential study based on COVAD surveys. Rheumatology. 2023;62(12):3838–3848. doi: 10.1093/rheumatology/kead144.
   PubMed Web of Science ®Google Scholar
• Petri M, Joyce D, Haag K, et al. Effect of systemic lupus erythematosus and immunosuppressive agents on COVID-19 vaccination antibody response. Arthritis Care Res. 2023;75(9):1878–1885.
   Web of Science ®Google Scholar
• Ruddy JA, Connolly CM, Boyarsky BJ, et al. High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021;80(10):1351–1352. doi: 10.1136/annrheumdis-2021-220656.
   PubMed Web of Science ®Google Scholar
• Geetha D, Dua A, Yue H, et al. Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases. Ann Rheum Dis. 2021;80(10):1357–1359. doi: 10.1136/annrheumdis-2021-220604.
   PubMed Web of Science ®Google Scholar
• Moyon Q, Sterlin D, Miyara M, et al. BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus. Ann Rheum Dis. 2022;81(4):575–583. doi: 10.1136/annrheumdis-2021-221097.
   PubMed Web of Science ®Google Scholar
• Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725–1725. doi: 10.1002/art.1780400928.
   PubMed Web of Science ®Google Scholar
• Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677–2686. doi: 10.1002/art.34473.
   PubMed Web of Science ®Google Scholar
• Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a lupus low disease activity state (LLDAS). Ann Rheum Dis. 2016 Sep;75(9):1615–1621. doi: 10.1136/annrheumdis-2015-207726.
   PubMed Web of Science ®Google Scholar
• Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005;353(24):2550–2558. doi: 10.1056/NEJMoa051135.
   PubMed Web of Science ®Google Scholar
• Takeshita M, Nishina N, Moriyama S, et al. Incomplete humoral response including neutralizing antibodies in asymptomatic to mild COVID-19 patients in Japan. Virology. 2021;555:35–43. doi: 10.1016/j.virol.2020.12.020.
   PubMed Web of Science ®Google Scholar
• Stoffel NU, Uyoga MA, Mutuku FM, et al. Iron deficiency anemia at time of vaccination predicts decreased vaccine response and iron supplementation at time of vaccination increases humoral vaccine response: a birth cohort study and a randomized trial follow-up study in kenyan infants. Front Immunol. 2020;11:1313. doi: 10.3389/fimmu.2020.01313.
   PubMed Web of Science ®Google Scholar
• Kanduc D, Shoenfeld Y. Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: implications for the vaccine. Immunol Res. 2020;68(5):310–313. doi: 10.1007/s12026-020-09152-6.
   PubMed Web of Science ®Google Scholar
• Talotta R. Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. Clin Immunol. 2021;224:108665. doi: 10.1016/j.clim.2021.108665.
   PubMed Web of Science ®Google Scholar
• Crowe SR, Merrill JT, Vista ES, et al. Influenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic features. Arthritis Rheum. 2011;63(8):2396–2406. doi: 10.1002/art.30388.
   PubMedGoogle Scholar
• Rodríguez Y, Rojas M, Beltrán S, et al. Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case reports and updated literature review. J Autoimmun. 2022;132:102898. doi: 10.1016/j.jaut.2022.102898.
   PubMed Web of Science ®Google Scholar
• Sachinidis A, Garyfallos A. COVID-19 vaccination can occasionally trigger autoimmune phenomena, probably via inducing age-associated B cells. Int J Rheum Dis. 2022;25(1):83–85. doi: 10.1111/1756-185X.14238.
   PubMedGoogle Scholar
• Pugès M, Biscay P, Barnetche T, et al. Immunogenicity and impact on disease activity of influenza and pneumococcal vaccines in systemic lupus erythematosus: a systematic literature review and meta-analysis. Rheumatology. 2016;55(9):1664–1672. doi: 10.1093/rheumatology/kew211.
   PubMed Web of Science ®Google Scholar
• Mok CC, Ho LY, Fong LS, et al. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis. 2013;72(5):659–664. doi: 10.1136/annrheumdis-2012-201393.
   PubMed Web of Science ®Google Scholar
• Mageau A, Tchen J, Ferré VM, et al. Impact of BNT162b2 mRNA anti-SARS-CoV-2 vaccine on interferon-alpha production by plasmacytoid dendritic cells and autoreactive T cells in patients with systemic lupus erythematosus: the COVALUS project. J Autoimmun. 2023;134:102987. doi: 10.1016/j.jaut.2022.102987.
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Porter FW, et al. mRNA vaccines – a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261–279. doi: 10.1038/nrd.2017.243.
   PubMed Web of Science ®Google Scholar
• Larsen ES, Nilsson AC, Möller S, et al. Immunogenicity and risk of disease flare after a three-dose regimen with SARS-CoV-2 vaccination in patients with systemic lupus erythematosus: results from the prospective cohort study COVAC-SLE. Clin Exp Rheumatol. 2023;41(3):676–684.
   PubMed Web of Science ®Google Scholar
• Assawasaksakul T, Sathitratanacheewin S, Vichaiwattana P, et al. Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in patients with SLE and rheumatoid arthritis. Lupus Sci Med. 2022;9(1):e000726. doi: 10.1136/lupus-2022-000726.
   PubMed Web of Science ®Google Scholar
• Madelon N, Lauper K, Breville G, et al. Robust T-Cell responses in anti-CD20-treated patients following COVID-19 vaccination: a prospective cohort study. Clin Infect Dis. 2022;75(1):e1037–e1045. doi: 10.1093/cid/ciab954.
   PubMed Web of Science ®Google Scholar
• Furer V, Rondaan C, Heijstek MW, et al. 2019 Update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39–52. doi: 10.1136/annrheumdis-2019-215882.
   PubMed Web of Science ®Google Scholar